Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1663-1665
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng, Bradley K. Ackerson, Katia Bruxvoort, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 90
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 49
Tracking the COVID-19 vaccines: The global landscape
Tushar Yadav, Swatantra Kumar, Gourav Mishra, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 48
Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19
Sara Y. Tartof, Jeff Slezak, Timothy B. Frankland, et al.
JAMA Internal Medicine (2024)
Open Access | Times Cited: 18
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs
Darvin Scott Smith, Maarten J. Postma, David N. Fisman, et al.
Vaccine (2025) Vol. 51, pp. 126879-126879
Closed Access | Times Cited: 1
Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
Daniel R. Feikin, Melissa M. Higdon, Nick Andrews, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2329-2338
Open Access | Times Cited: 29
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 160-160
Open Access | Times Cited: 28
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 6, pp. 581-593
Open Access | Times Cited: 7
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Eliel Nham, Joon Young Song, Ji Yun Noh, et al.
Journal of Korean Medical Science (2022) Vol. 37, Iss. 47
Open Access | Times Cited: 33
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 7
Open Access | Times Cited: 6
AVERTED MORTALITY BY COVID-19 VACCINATION IN BELGIUM BETWEEN 2021 AND 2023
Veerle Stouten, Izaak Van Evercooren, Catharina Vernemmen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults
Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, et al.
Current Medical Research and Opinion (2025), pp. 1-21
Closed Access
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy
Abby E. Rudolph, Farid Khan, Amy Shah, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 3, pp. 648-659
Open Access | Times Cited: 14
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
The Lancet Healthy Longevity (2023) Vol. 4, Iss. 8, pp. e409-e420
Open Access | Times Cited: 13
BNT162b2 XBB1.5-adapted Vaccine and COVID-19 Hospital Admissions and Ambulatory Visits in US Adults
Sara Y. Tartof, Jeff Slezak, Timothy B. Frankland, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 13
An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight
Shoaib Shoaib, Mohammad Azam Ansari, Geetha Kandasamy, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 795-795
Open Access | Times Cited: 12
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
Alberto Mateo‐Urdiales, Chiara Sacco, Daniele Petrone, et al.
JAMA Network Open (2023) Vol. 6, Iss. 10, pp. e2336854-e2336854
Open Access | Times Cited: 12
The real-time infection hospitalisation and fatality risk across the COVID-19 pandemic in England
Thomas Ward, Martyn Fyles, Alex Glaser, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants
Charles B. Stauft, Prabhuanand Selvaraj, Felice D’Agnillo, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector P. Rodríguez, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1194-1203
Open Access | Times Cited: 10
Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top